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Guidelines for biliary cancer - a step forward
This issue of HPB sees the publication of the outcomes from the AHBPA Consensus Conference on the Multidisci-
plinary Management of Bile Duct Cancer held in San Francisco in January earlier this year. The three resulting articles
by Weber, Aloia and Mansour highlight the challenges posed by both hilar and intrahepatic cholangiocarcinoma as well
as gallbladder cancer, providing up-to-date evidence in the management for these increasingly common and deadly
diseases. The accompanying editorials focus on the key unresolved issues that will be the centre of future research
endeavour and give a flavour of how future therapeutic strategies may evolve. The Consensus group is to be congratu-
lated in analysing the current evidence available on how best to manage these malignancies. We have to accept that
high-level evidence is not widely available to deliver strong support for some of the recommendations, but the guide-
lines represent the best state of the art guidance and propose logical criteria on which to base future investigations.
The readership of HPB now have access to not only the latest evidence, but they will now be well aware of those areas
where new evidence is desperately required to improve outcomes for this series of challenging diseases. HPB surgeons
are encouraged not just to publish their experience in managing these three distinct entities but to report outcomes
against these current standards of care. Better still, it would be wonderful to see some prospective studies and trials to
improve the evidence base and make a difference in the future.
O. James Garden
Enhanced recovery after liver surgery: safety and efficacy
Enhanced recovery after surgery (ERAS) programmes have taken the surgical world by storm. Liver surgery is no
exception and a number of studies have examined the role of ERAS in this branch of surgery.
In this edition of HPB, Dasari and colleagues from Birmingham, UK looked at outcomes of patients undergoing
liver resection for a 6 month period before and after implementing a structured ERAS programme. What they found
was that there was a reduction in post-operative complications but not in post-operative length of stay. Many ERAS
intervention studies have reported a reduction in length of stay or time to functional recovery and in this study the
authors attributed the lack of difference to age and comorbidity, but it may be they had already adopted practices
associated with enhanced recovery as part of their standard management but before implementation of a formal ERAS
programme. The reduction in complications is interesting because this pertained to a number of different complica-
tions with no obvious common thread. This finding probably supports the notion that it is the complete package of
ERAS elements that contributes to improved outcome rather than one or two particular elements.
This study excluded certain groups of patients including those undergoing ALPPS, concomitant biliary or vascular resec-
tion and those undergoing living donation procedures. The first two groups are understandable but a strong case can be
made for early mobilization and enhanced recovery of patients undergoing living liver donation, particularly if as in this
study, it is associated with lower complication rates.
Stephen J. Wigmore
Skunking of the liver: novel and interesting but how should it be
monitored?
HPB surgery is in an era where technology is allowing the rapid development of new and exciting procedures. The
ethical considerations around the introduction of such technology remain challenging and poorly defined. Surgical
history is littered with patient harm from the uncontrolled introduction of new procedures with laparoscopic chole-
cystectomy being such an example.
In this issue of HPB, Klink and colleagues report a series of 10 patients with refractory hepatic abscesses in whom they have
performed minimally invasive hepatic abscess debridement using techniques learnt thru the authors experience with mini-
mally invasive pancreatic necrosectomy. All patients were successfully managed with minimal morbidity and no mortality.
In reading this paper the described logic and novelty piques ones interest but like all good papers it also raises sig-
nificant questions and concerns about whether similar favourable outcomes can be achieved by others if implemented
elsewhere. The indications for such a procedure are listed as failure to improve clinically or radiologically after one
drainage. Yet, one does not expect early radiological resolution with hepatic abscesses. No indication is given as to
whether a significant period of non-intervention is important to ensure a well walled off cavity or if patients were
considered for upsizing the drains or use of irrigant that might help breakdown loculations. In addition, potential
contraindications such as proximity to major hepatic venous structures were not listed. Does the cavity need to be
irrigated during the procedure to avoid risk of air embolism or does this create a high pressure system leading to
septic shower? Although informed consent was obtained from individual patients, there is no mention of ethical
approval or of a data monitoring committee to identify adverse outcomes. Are these data from a compulsory registry
or is a select group of patients reported from centres of excellence?
The striking finding is that these abscesses seem to be ‘first world etiologies’, almost all following complications of
major surgical intervention with or without possible biliary obstruction or vascular compromise. This raises questions
about the presence of significant associated hepatic necrosis. No data are provided about possible drain occlusion
during irrigation and the potential for septic shower as seen in patients undergoing pancreatic necrosectomy.
Communication with the biliary tree is an additional risk and irrigation may result in biliary sepsis if distal obstruc-
tion is present. Detailed data regarding these issues aren’t provided making interpretation difficult.
So although these results seem promising for a small and presumably well selected group of patients surely this is
exactly the type of innovation that requires a mandatory registry. The question is who should be responsible for this?
Saxon Connor
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